© The Financial Times Ltd 2015 FT and 'Financial Times' are trademarks of The Financial Times Ltd.
As of Jul 24, 2015, the consensus forecast amongst 23 polled investment analysts covering Gilead Sciences, Inc. advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Oct 21, 2009. The previous consensus forecast advised investors to purchase equity in Gilead Sciences, Inc..
|Last year||3 months ago||2 months ago||4 weeks ago||Latest|
The 19 analysts offering 12 month price targets for Gilead Sciences, Inc. have a median target of 125.00, with a high estimate of 159.00 and a low estimate of 95.00. The median estimate represents a 10.55% increase from the last price of 113.07. View Full Financials
Historical dividend information is not available for Gilead Sciences Inc. View Full Financials
|Div growth (TTM)||--|
On Jul 28, 2015, Gilead Sciences, Inc. reported 2nd quarter 2015 earnings of 3.15 per share. This result exceeded the 2.71 consensus of the 19 analysts covering the company and exceeded last year's 2nd quarter results by 33.47%. View Full Interim Financials
|Average growth rate||+8.38 %|
Gilead Sciences, Inc. reported annual 2014 earnings of 8.09 per share on Feb 03, 2015. View Full Annual Financials
|Average growth rate||+76.71 %|
Gilead Sciences Inc. had 2nd quarter 2015 revenues of 8.24bn. This bettered the 7.61bn consensus of the 18 analysts covering the company. This was 26.15% above the prior year's 2nd quarter results. View Full Interim Financials
|Average growth rate||+6.47 %|
Gilead Sciences Inc. had revenues for the full year 2014 of 24.89bn. This was 122.20% above the prior year's results. View Full Annual Financials
|Average growth rate||+39.71 %|